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The mammalian intestinal epithelium forms an absorptive barrier 
that separates a vast and diverse population of luminal microbes 
(1–3) from the robust capillary networks and immune cell popula-
tions located in the underlying mesenchyme of the host (4–5). Dis-
ruption or perturbation of this barrier can come from a number 
of sources, including irradiation as well as infection by pathogenic 
organisms and cytotoxic chemicals. Because of the unique ecol-
ogy of the intestine, regulators of barrier maintenance and repair 
must be deployed in a rapid fashion. A focal point for this process 
is the proper modulation of colonic epithelial progenitor (ColEP) 
activity. Our goal in these studies was to determine the roles of 
the epithelium, the surrounding mesenchymal niche, and various 
inflammatory cells in making and executing these important deci-
sions in response to a given injury.
The barrier epithelium that lines the inner surface of the mouse 
cecum and colon is a single layer of nondividing, terminally dif-
ferentiated cells. These cells undergo constant and rapid replace-
ment during the life of the organism. The source of this renewal 
is a proliferative population of ColEPs, located in the lower third 
of epithelial invaginations (called “crypts of Lieberkühn”) (6). 
ColEPs consist of tripotent stem cells that give rise to 2 sets of 
proliferative committed daughters; monopotent progenitors 
produce absorptive enterocytes, while bipotent progenitors give 
rise to secretory goblet and enteroendocrine cells. All 3 epithelial 
lineages continue their differentiation program as they migrate 
upward toward the luminal surface (7). Enterocytes are the pre-
dominant cell type that exits the crypt and forms the surface bar-
rier epithelium. Most goblet cells remain in the crypt, and their 
precise localization within this structure depends on their ana-
tomic location along the length of the colon.
During homeostasis, Wnt and Notch signals are required to 
maintain ColEP proliferation, while TGF-β and bone morpho-
genetic protein act as key negative regulators. Wnt, Notch, and 
Hedgehog signaling all play a role in modulating intestinal epi-
thelial cell fate decisions (e.g., refs. 8–12). A key source of many of 
these signals is considered to be the stem cell niche (13, 14). In the 
colon, the niche is composed of mesenchymal cellular networks 
of fibroblasts and blood vessels that envelop crypts and project 
toward the surface epithelium. Most colonic fibroblasts are myofi-
broblasts that express a subset of smooth muscle–specific proteins 
and form a prominent anastamosing network of cells that forms a 
cup-like structure around each crypt (15). These cells may produce 
a variety of factors that support crypt proliferation and may dis-
play	an ability to migrate upward toward that luminal surface in 
concert with the overlying epithelial cells (16). The microvascula-
ture has also been proposed to play a role in ColEP survival during 
irradiation injury (17). The role of nonmyogenic fibroblasts in the 
crypt-associated mesenchyme is unclear.
During certain types of injury, the crypt base niche requires a cel-
lular adaptation from the immune system to properly support the 
overlying epithelial response that is required for the overall health of 
the animal. In a chemical injury model involving oral introduction 
of dextran sodium sulfate (DSS), mice that are deficient for either 
indigenous colonic microbes or TLR signaling have diminished sur-
vival and more severe weight loss because ColEPs no longer divide 
at an appropriate rate to properly maintain the epithelial barrier 
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(18–21). In a previous study, we found that macrophages, activated 
by TLR signaling, are recruited to the colonic stem cell niche and are 
required for the proper epithelial response to this injury (18).
Our previous microarray experiments using laser capture micro-
dissected cells from the pericryptal mesenchyme surrounding hyper-
proliferative crypts and hypoproliferative crypts from DSS-injured 
mice identified prostaglandin-endoperoxide synthase 2 (Ptgs2 or Cox-2) 
as a candidate mediator of the ColEP response (18). In the intestine, 
Ptgs2 is expressed in a small subset of lamina propria stromal cells, 
while its homolog, Ptgs1, is expressed primarily in the crypt epithe-
lium and lamina propria mononuclear cells (22–24). Together, they 
play a vital role in the production of prostaglandins that can have 
both growth-stimulatory	and antiapoptotic effects (25). Ptgs1 and -2 
have also been shown to play a significant role in protection of the 
intestine from both irradiation and DSS-mediated damage (24, 26, 
27), primarily though the production of PGE2. Recently PGE2 was 
shown to transactivate the canonical Wnt signaling pathway (28).
Because signaling through Myd88-dependent TLRs and Ptgs2 
(through PGE2) play similar roles in limiting gut injury to a variety 
of stimuli, we hypothesized that these pathways might be either 
coordinated or linked during the injury response. In this study, we 
evaluated the role of Ptgs2 and its relationship with Myd88 sig-
naling in mice injured with DSS. We found that absence of either 
Myd88 or Ptgs2 in DSS-treated mice profoundly inhibited ColEP 
proliferation in the mouse rectum. We found that exogenous 
16,16-dimethyl PGE2 (dmPGE2) rescued this effect in both knock-
out mice, establishing that Ptgs2 and PGE2 were downstream of 
Myd88 signaling. Surprisingly, Myd88 did not modulate Ptgs2 
expression, but instead altered the positioning of Ptgs2-express-
ing stromal cells (PSCs) in the lamina propria mesenchyme relative 
to ColEPs in the crypt base. This represents what we believe to be 
a novel finding of a cellular niche modification that is required to 
maintain colonic epithelial proliferation in response to injury.
Results
The crypt epithelial response to DSS-mediated rectal injury was similar 
in Ptgs2–/– and Myd88–/– mice. We previously showed that treat-
ment of WT adult, male C57BL/6J (B6) mice with 2.5% DSS for 
1 week resulted in colonic injury in the form of focal ulcers in the 
descending colon and a single confluent ulcer at the ano-rectal 
junction (18) (Figure 1A). The crypts surrounding the ulcers in the 
descending colon were elongated and contained an expansion of 
ColEPs. This process depended on the presence of microbes in the 
lumen, detection during injury by host bone marrow–derived cells 
through Myd88-dependent TLR signaling, and presence of activat-
ed macrophages in the crypt base niche (18). In contrast, the rectal 
tissue between these major injury sites was not severely injured in 
DSS-treated WT mice (Figure 1A, boxed area). By whole mount 
analysis, the mucosal surface of this area was uniform and did not 
contain ulcers (n = 20). Low-power histologic analysis of this area 
of the rectum showed that the cellularity of the mesenchyme and 
the density and architecture of crypt-surface units was not percep-
tibly altered when similar regions of untreated and DSS-treated 
WT mice were compared (Figure 1, B and C).
As Myd88–/– and Ptgs2–/– mice are susceptible to DSS-mediated 
damage in the colon (18–21, 26) and PGE2 can play a role in the 
amelioration of DSS-induced damage in WT mice (24), we hypoth-
esized that a mechanistic link exists between Myd88 and Ptgs2 sig-
naling pathways that protects the colonic mucosa from this type 
of damage. We evaluated the response to DSS-mediated injury in 
the rectums of Myd88–/– and Ptgs2–/– mice using our experimental 
protocol. Low-power histologic views of the rectums from untreat-
ed Myd88–/– and Ptgs2–/– mice did not show significant differences 
in the morphology of crypt-surface epithelial units and the overall 
Figure 1
Myd88–/– and Ptgs2–/– mouse rectums were susceptible to DSS-induced 
injury. (A) Colon whole mount from an adult WT B6 mouse treated with 
2.5% DSS for 1 week. The DSS-induced lesions (top) and the cor-
responding anatomic locations (bottom) are indicated. All strains ana-
lyzed in this study showed multiple small (<0.5 mm in diameter) ulcers 
with heaped borders in the descending colon and a confluent ulcer 
that extended from the ano-rectal junction proximally (0.5–1.0 cm). 
The intervening area in the remaining rectum (yellow boxed area) was 
spared of ulcerative injury. (B–G) H&E-stained sections of the rectums 
from adult B6 WT (B and C), Myd88–/– (D and E), and Ptgs2–/– (F and 
G) mice. (B, D, and F) Untreated mice. (C, E, and G) Mice treated for 7 
days with 2.5% DSS in the drinking water. The rectums from WT DSS-
treated mice were indistinguishable from those of untreated WT mice. 
However, DSS-treated Myd88–/– and Ptgs2–/– mice both showed a 
similar pattern of crypt area loss manifested by alterations in crypt mor-
phology (including angulation and dilation of the base; arrows) as com-
pared with untreated controls. Scale bars: 1 cm (A), 100 μm (B–G).
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cellularity of the underlying lamina propria mesenchyme as com-
pared with WT mice (Figure 1, B, D, and F).
The gross appearance of whole mount preparations of the colons 
from DSS-treated Myd88–/– and Ptgs2–/– mice showed an overall pat-
tern of injury similar to that in WT DSS-treated mice. Ulcers were 
observed in the descending colon and ano-rectal junction, while 
the intervening rectal mucosa of both knockout strains was ulcer-
free (data not shown). However, low-power histologic views of the 
rectums from DSS-treated Myd88–/– and Ptgs2–/– mice showed that 
crypts were much less prominent as compared with those in rectums 
from similarly treated WT mice and their untreated counterparts. 
While the number of crypts per unit area was not altered in the mice, 
each sectioned crypt contained less surface area (corresponding to 
less volume in 3 dimensions). Crypt morphology was typically altered 
to increase either lumen size or angulation of the base (Figure 1, E 
and G). The loss of crypt volume corresponded to an increase in the 
mesenchymal area of both Myd88–/– and Ptgs2–/– DSS-treated mice, 
though the overall cellular density in this region was not percepti-
bly altered. These effects were specific for the absence of Ptgs2, as 
rectums from DSS-treated Ptgs1–/– mice had the same overall appear-
ance as those from WT DSS-treated mice (data not shown).
Both Ptgs2 and Myd88 were required to maintain crypt organization and 
epithelial proliferation during DSS-mediated injury. Because rectal crypt 
alterations were prominent in DSS-treated Myd88–/– and Ptgs2–/– 
mice, we evaluated goblet cells and ColEPs, the 2 major cell types 
in this microanatomic compartment. To visualize goblet cells, we 
used a pan-mucin stain that labels both neutral and acidic muco-
substances (PAS/Alcian blue [PAS/AB] stain) (29). Fully differenti-
ated goblet cells (containing a single large apical theca) were located 
primarily in the upper half of rectal crypts from untreated WT mice. 
The lower half of crypts consisted primarily of ColEPs that showed 
scant, diffuse PAS/AB cytoplasmic staining. A subset of the ColEPs 
showed focal staining in smaller apical thecae, consistent with com-
mitted goblet cell progenitors (Figure 2A) (6). The overall distribu-
tion of goblet cells and ColEPs was not perceptibly altered in either 
DSS-treated WT mice (Figure 2B) or untreated Myd88–/– and Ptgs2–/– 
mice (Figure 2, C and E). However, goblet cells in rectal crypts of 
DSS-treated Myd88–/– and Ptgs2–/– mice were distributed throughout 
rectal crypts (Figure 2, D and F).
Because goblet cells appeared to be a more prominent component 
of rectal crypts in Myd88–/– and Ptgs2–/– DSS-treated mice, we con-
sidered that epithelial differentiation was altered to preferentially 
Figure 2
Goblet cell reorganization and loss of epithelial proliferation in the rectum of DSS-treated Ptgs2–/– and Myd88–/– mice. (A–F) Sections of a rectal 
crypt-surface unit from WT (A and B), Myd88–/– (C and D), and Ptgs2–/– (E and F) mice. (A, C, and E) Untreated mice. (B, D, and F) DSS-treated 
mice. Sections were stained with PAS/AB to identify goblet cells (left) or with goat anti-BrdU, Alexa-Fluor 594–labeled donkey anti-goat Ig (red), and 
bis-benzimide (blue nuclear stain) to identify cells in S-phase (right). Scale bars: 20 μm. The crypt epithelial-mesenchymal (dotted lines) and the 
epithelial crypt-surface junctions (dashed lines) are indicated. Quantification of goblet cells per crypt (G), crypt cell census (H), crypt height (I), epi-
thelial apoptosis (J), and epithelial proliferation (K). Mean values ± SEM were plotted for each group. An asterisk indicates a value that is statistically 
significantly different from the corresponding untreated control (*P < 0.001; Student’s t test). Both DSS-treated Myd88–/– and Ptgs2–/– mice showed 
a statistically significant decrease in epithelial proliferation and crypt cell census as compared with their corresponding untreated controls.
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favor selection of secretory lineages, perhaps through an inhibi-
tion of Notch signaling (9). However, the number of goblet cells per 
crypt was not altered either by genotype or by DSS-mediated injury 
(Figure 2G). Goblet cells appeared to be more prominent, as rectal 
crypts from DSS-treated Myd88–/– and Ptgs2–/– mice contained sig-
nificantly fewer total cells per crypt (Figure 2H; each DSS-treated 
knockout mouse contained less than half the cells of its untreated 
counterpart; P < 0.001; n = 3–5 mice/group, 100 well-oriented rectal 
crypts evaluated/mouse; “well-oriented” was defined as the crypt 
lumen being present from the top to the bottom of the crypt), thus 
increasing the fractional representation of this lineage. Interestingly, 
although Myd88–/– and Ptgs2–/– rectal crypts contained fewer cells, 
they were not significantly shortened as a result of DSS treatment 
(Figure 2I). Thus, alterations in overall crypt morphology and indi-
vidual cells created the striking images that defined the phenotype 
at low-power histology.
The loss of cells within rectal crypts of DSS-treated Myd88–/– and 
Ptgs2–/– mice could have resulted from diminished epithelial input 
(proliferation) and/or increased outflow (cell death). Therefore, 
we scored for proliferation by quantifying M-phase cells per crypt 
and for cell death by quantifying apoptotic bodies per crypt-sur-
face unit within the epithelium. We found no significant differ-
ences in epithelial cell death when comparing untreated and DSS-
treated mice of any genotype (Figure 2J). We obtained the same 
results when we evaluated the crypt and the surface epithelium 
separately (data not shown). However, quantification of M-phase 
cells per crypt showed that Ptgs2–/– and Myd88–/– mice treated with 
DSS showed a significant decrease in epithelial proliferation when 
compared with their untreated counterparts (Figure 2K; prolifera-
tion in each knockout was less than 10-fold that of its untreated 
counterpart; P < 0.001; n = 3–5 mice/group, 100 well-oriented rec-
tal crypt-surface units evaluated/mouse). In support of this find-
ing, S-phase cells located in the lower third of normal crypts were 
nearly absent in DSS-treated Ptgs2–/– and Myd88–/– mice (Figure 2, 
A–F). Thus, a major target of the DSS-mediated effects was the 
proliferative activity of the ColEPs.
No significant inflammatory infiltrates occurred in the rectum of DSS-
treated mice. Previously, we found that the lamina propria mesen-
chyme underlying crypts that bordered ulcers in WT DSS-treated 
mice showed a substantial influx of inflammatory cells, including 
neutrophils, lymphocytes, and macrophages (18). Similar areas of 
DSS-treated Myd88–/– mice showed no significant increase in lym-
phocytes and neutrophils. The influx of macrophages was similar 
to that in WT mice, though the macrophages were not activated 
either morphologically or molecularly in the absence of Myd88. In 
contrast, the rectal mesenchyme of WT DSS-treated mice showed 
no statistically significant alteration in immune cell populations. 
DSS-treated Myd88–/– and Ptgs2–/– mice showed a minimal influx 
of lymphocytes and neutrophils (not statistically significant) and 
no increase in macrophages in the rectum (Figure 3; n = 3–5 mice 
evaluated/group; lamina propria mesenchyme associated with 300 
well-oriented perpendicular sections through crypt-surface units/
mouse). We concluded that the near ablation of rectal epithelial 
proliferation in DSS-treated Myd88–/– and Ptgs2–/– mice could not 
be explained simply as a response to inflammation.
Exogenous dmPGE2 rescued the DSS-mediated rectal injury in both 
Ptgs2–/– and Myd88–/– mice. Because the phenotype of the rectal 
mucosa of DSS-injured Myd88–/– and Ptgs2–/– mice was similar by 
all quantitative morphometric parameters, we tested the hypoth-
esis that these genes functioned in the same genetic pathway, with 
Ptgs2 downstream of Myd88. We attempted to rescue the pheno-
type of DSS-treated Myd88–/– mice with a key prostaglandin pro-
duced in the intestine (PGE2) that is regulated in part by Ptgs2 
(24). For in vivo administration, we used dmPGE2, which has pre-
viously been utilized and exhibits a longer half-life compared with 
endogenous PGE2 (23).
We evaluated multiple doses of dmPGE2 in DSS-treated WT and 
Ptgs2–/– mice. Injection of 10 μg dmPGE2/kg body weight twice per 
day during the 7 days DSS treatment did not alter the rectal muco-
sal morphology of WT DSS-treated mice by any of the previously 
described morphometric parameters (Figure 4A). Higher doses of 
dmPGE2 partially inhibited rectal epithelial proliferation in WT 
DSS-treated mice (data not shown). The treatment regimen of 
dmPGE2, optimized for WT DSS-treated mice, completely rescued 
the crypt alterations (dysmorphic crypts and goblet cell disorga-
nization) that occurred in DSS-treated Ptgs2–/– mice (Figure 4B). 
Quantification of key aspects associated with the phenotype 
showed that epithelial proliferation and the crypt census occurred 
at levels comparable to those in WT DSS-treated mice (Figure 4, 
D and F; P < 0.001; n = 5 mice/group).
The same regimen of dmPGE2 also rescued the rectal phenotype 
of DSS-treated Myd88–/– mice (Figure 4C). Importantly, epithelial 
proliferation and crypt census in these mice were significantly dif-
ferent from those in controls (DSS-treated Myd88–/– mice in the 
absence of exogenous dmPGE2) and were comparable to those in 
DSS-treated WT and Ptgs2–/– mice with the addition of this drug 
(Figure 4, D and F; P < 0.001; n = 5 mice/group). Parameters not pre-
viously altered by DSS treatment, including apoptosis (Figure 4E), 
goblet cell number, and crypt height (data not shown), were also 
unaltered by the addition of dmPGE2.
Ptgs2 mRNA transcripts were expressed in the mesenchyme but were 
not increased by injury or Myd88 status. The rescue of DSS-treated 
Myd88–/– mice by dmPGE2 showed that Ptgs2 acted downstream of 
Myd88. Our goal was to discern the precise relationship between 
these 2 genes that required both to prevent the loss of rectal ColEP 
proliferation during DSS injury. Our initial hypothesis was that 
Myd88 signaling regulated Ptgs2 expression.
To test this idea, we established a quantitative assay for the micro-
anatomic localization of Ptgs2 transcripts. We used laser capture 
microdissection (LCM) to separately procure rectal mesenchymal 
Figure 3
There was no statistically significant inflammatory infiltrate in the rectum 
of DSS-treated mice. Quantification of lymphocytes (B220 and CD3ε), 
neutrophils and eosinophils (Gr-1), and macrophages (F4/80) per crypt-
surface unit. Mean values ± SEM were plotted for each group. No sta-
tistically significant differences were observed when comparing any of 
the DSS-treated mice with untreated mice (Student’s t test; P < 0.05).
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lamina propria and epithelial cells (both crypt and surface cells 
together) for quantitative RT-PCR (qRT-PCR) assays that compared 
Ptgs2 transcript levels in these 2 cellular compartments. Total RNA 
was isolated from each cellular compartment from 4 experimental 
groups (WT and Myd88–/– both with and without DSS treatment). 
The resulting cDNAs were used for SYBR Green–based qPCR detec-
tion of 10 genes. For each gene, the threshold cycle (CT) for each 
amplicon was subtracted from a baseline (18S rRNA) to calculate 
a change in CT (ΔCT). For pair-wise comparisons, the mesenchymal 
ΔCT (numerator) was divided by its corresponding epithelial ΔCT 
(denominator) to calculate a fold difference.
As a control for the relative transcript enrichment within a given 
compartment, we used the same cDNAs to analyze transcripts 
that are preferentially expressed in the mesenchyme (vimentin) 
and epithelium (E-cadherin) as previously described (18, 30, 31). 
Mesenchymal dissections contained a 9-fold enrichment of vimen-
tin transcripts as compared with material from epithelial dissec-
tions performed on the same sections (Figure 5A; n = 12 mice), 
while epithelial dissections contained a 5-fold enrichment of E-cad-
herin transcripts as compared with the mesenchyme (Figure 5A). 
These data were pooled from comparisons using material from all 
4 experimental groups (WT and Myd88–/– both with and without 
DSS treatment). Each individual group contained comparable lev-
els of enrichment of vimentin and E-cadherin (data not shown).
We used the enrichment of E-cadherin transcripts in the epithe-
lium and vimentin transcripts in the mesenchyme as benchmarks 
to compare the localization of other transcripts. We performed 
additional qRT-PCR analysis using the same set of microdis-
sected material for markers of mesenchymal cells that might 
express Ptgs2 (e.g., F4/80 for macrophages; CD11c for dendritic 
cells; Pecam for endothelial cells). Each of these cellular mark-
ers was enriched in the mesenchyme (similar to vimentin) for all 
experimental groups (a mean of 4.5- to 7-fold; Figure 5A). Each 
of the 4 experimental groups contained similar levels of tran-
script enrichment in the mesenchyme (data not shown).
Using the same microdissected material that was used for the dis-
section controls, qRT-PCR analysis showed that Ptgs2 transcripts 
were elevated in the mesenchyme 5-fold, a level of enrichment com-
Figure 4
Exogenous dmPGE2 rescued the rectal phenotype of DSS-treated Ptgs2–/– and Myd88–/– mice. (A–C) H&E-stained sections of rectums from (A) 
WT, (B) Ptgs2–/–, and (C) Myd88–/– mice that were concurrently treated with DSS and 10 μg/kg dmPGE2. In all cases, the low-power view of the 
rectum was similar to that of WT DSS-treated mice in the absence of exogenous dmPGE2 (Figure 1C). Scale bars: 100 μm. (D–F) Quantification of 
(D) epithelial proliferation, (E) epithelial apoptosis, and (F) crypt cell census. Mean values ± SEM were plotted for each group. An asterisk indicates 
a value that is statistically significantly different from the corresponding control that did not receive dmPGE2 (*P < 0.001; Student’s t test). This dos-
age of dmPGE2 did not affect the rectum of WT DSS-treated mice and rescued the rectal phenotype of DSS-treated Ptgs2–/– and Myd88–/– mice.
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parable to that of all of the other mesenchymal markers (Figure 5A), 
suggesting this was the primary microanatomic site of Ptgs2 expres-
sion. As a control, material from a Ptgs2–/– mouse was used to obtain 
a null signal (data not shown). We also evaluated other genes we 
previously identified as enriched in WT DSS-treated mice relative 
to Myd88–/– DSS-treated mice (18). We found that transcripts for an 
interferon inducible GTPase 1 (Iigp1) were also enriched in the mesen-
chyme while indoleamine-pyrrole 2,3 dioxygenase (Indo) and regenerating 
islet-derived 3γ (Reg3g) were preferentially expressed in the epithelium 
using the exact same set of microdissected material (Figure 5A).
We then determined the regulation of mesenchymal Ptgs2 tran-
script abundance by making 3 separate pair-wise comparisons 
between (a) untreated and DSS-treated WT mice, (b) untreated 
and DSS-treated Myd88–/– mice, and (c) DSS-treated WT and 
DSS-treated Myd88–/– mice. As Ptgs2 transcripts were prefer-
entially located in the mesenchyme, we performed these com-
parisons using material from this microanatomic compartment. 
Surprisingly, no statistically significant differences in Ptgs2 tran-
script abundance were found for any of these 3 comparisons 
(Figure 5B; n = 3 mice/group). Therefore, neither the status of 
injury nor Myd88 affected Ptgs2 expression in this system.
As a control for the injury response in WT versus Myd88–/– rec-
tums, we evaluated transcript levels of Iigp1, Indo, and Reg3g using 
exactly the same set of LCM-procured samples and the same set of 
pair-wise comparisons. In contrast to Ptgs2, all 3 of these transcripts 
showed significant Myd88- and injury-dependent alterations in 
transcript abundance in the microanatomic compartment where 
they were preferentially expressed. In the mesenchyme, Iigp1 was 
enriched (smaller ΔCT) in WT DSS-treated mice as compared with 
WT untreated (Figure 5D; 5-fold difference; P < 0.05) and Myd88 
DSS-treated	mice (19-fold difference; P < 0.05). Similar enrich-
ments were observed with the 2 epithelially expressed genes (Indo 
and Reg3g). Transcripts for Indo were enriched in WT DSS-treated 
mice as compared with WT untreated mice (Figure 5C; 39-fold dif-
ference; P < 0.05). Reg3g was an extreme case because transcripts were 
only detected in the WT DSS-treated samples, and thus comparative 
calculated comparisons could not be performed (Figure 5E).
Myd88 signaling redistributed the location of PSCs toward the crypt base 
epithelium. Because Ptgs2 mRNA levels were not altered in response 
to DSS-mediated injury, we evaluated the cellular origin and quan-
tified the location of PSCs by examining immunohistochemically 
stained sections of WT and Myd88–/– rectums (both with and without 
DSS treatment) with antibodies directed against Ptgs2. In all cases, 
we found scattered, elongated Ptgs2-positive–stained cells restrict-
ed to the lamina propria mesenchyme (e.g., WT DSS; Figure 6). 
Occasional 2-cell clusters were observed. Similarly stained rectums 
from Ptgs2–/– mice showed no staining (data not shown).
PSCs were previously identified in the normal small intestine 
(22) and are increased by irradiation injury and early adenoma for-
mation (23, 32). However, no definitive cell-surface markers have 
been identified to characterize these cells. We found that PSCs in 
both untreated and DSS-treated WT and Myd88–/– mice showed 
robust staining for CD44 (Figure 6, A–C; n = 3 mice/group). As 
this surface marker can be expressed by a variety of immune and 
fibroblast cell types, we attempted to further characterize this cell 
type. We found variable weak to absent staining of PSCs with the 
general leukocyte marker CD45 (Figure 6, D–F) in all experimental 
groups. However, PSCs were uniformly negative for all of the well-
Figure 5
Ptgs2 transcripts expressed in the lamina propria mesenchyme were not elevated in response to injury. (A) qRT-PCR analysis of LCM-procured 
mRNAs from the rectal mucosal mesenchyme versus the overlying epithelium. A positive value (green) indicated transcript enrichment in the mes-
enchyme, and a negative value (red) indicated enrichment in the epithelium. The SEM of the fold difference for each gene was calculated from the 
averages of each experimental group analyzed (WT and Myd88–/– mice with and without DSS treatment). Dissection controls included vimentin, 
Pecam1, CD11c, and F4/80 for the mesenchyme and E-cadherin (E-cad) for the epithelium. Ptgs2, Iigp1, Indo, and Reg3g were identified in our 
prior microarray screens for transcripts elevated with DSS injury (boxed region). Ptgs2 and Iigp1 were enriched in the mesenchyme, while Indo 
and Reg3g were enriched in the epithelium. (B–E) Shown are mean ± SD of ΔCTs for Ptgs2 (B), Indo (C), Iigp1 (D), and Reg3g (E) as measured 
from the compartment where the transcript was enriched. A smaller ΔCT indicates greater expression. The relative transcript levels for Ptgs2 were 
not significantly different between DSS-treated and untreated controls for either WT or Myd88–/– rectal mesenchyme. Both Iigp1 and Indo were 
significantly enriched in DSS-treated WT mice (versus untreated). Signal for Reg3g was only detected in the WT DSS-treated sample.
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characterized hematopoietic lineage markers, including F4/80 
(macrophages; Figure 6, G–I), CD11c (DCs), CD11b, B220 (B 
cells), CD3ε (T cells), NK1.1 (B6 NK cells), Gr-1 (neutrophils and 
eosinophils), c-Kit (mast cells), and CD70 (data not shown) (33). 
In addition, markers for fibroblasts/myofibroblasts also failed to 
show colocalization with PSCs, including anti–α-SMA (Figure 7, 
A–D), laminin, propyl 4-hydroxylase, and fibroblast-specific pro-
tein 1	(data not shown). PSCs also did not express endothelial 
(Pecam1) or ganglion cell (neuron β-tubulin) markers under any 
of the experimental conditions. Thus, we define PSCs as CD44+, 
differentiated hematopoietic lineage–negative, myofibroblast lin-
eage–negative cells and interpret these as a subpopulation that has 
not been previously characterized in the mouse colon.
Quantitative analysis showed that under all experimental condi-
tions used in this study, the number of PSCs per crypt-surface unit 
was approximately 25-fold lower than F4/80-positive macrophages. 
In addition, no statistically significant differences in the number of 
PSCs were found when we compared untreated with DSS-treated 
mice (both WT and Myd88–/–; Figure 7E; n = 6–8 mice/group).
Because Ptgs2 transcript abundance and the number of PSCs 
were not altered by injury or Myd88 signaling, we measured PGE2 
levels in the entire rectum (Table 1). We found that the levels of 
this key prostaglandin were not significantly altered in WT mice 
that were treated with DSS (see ref. 24 for examples of significant 
alterations). Also, DSS-treated Myd88–/– and Ptgs2–/– mouse rec-
tums both contained levels of PGE2 similar to those in WT DSS-
treated mice. This is further evidence that neither Ptgs2 expression 
nor its activity was dependent on injury or Myd88 gene status.
We observed that most PSCs were localized near the crypt base 
in WT DSS-treated mice, while other crypt niche constituents 
such as myofibroblasts were not noticeably reorganized (Figure 7, 
A–D). We quantified the localization by counting the PSCs asso-
ciated with 3 distinct mesenchymal locations: the crypt base 
(adjacent to proliferative ColEPs), the mid-crypt (adjacent to 
postmitotic epithelial cells), and the crypt surface (adjacent to 
terminally differentiated epithelial cells). We found that untreat-
ed WT and Myd88–/– mice as well as DSS-treated Myd88–/– mice 
all showed the same distribution of PSCs, with the majority of 
the cells present in the mid-crypt zone. However, DSS-treated 
WT mice showed a statistically significant redistribution of cells 
from the upper and mid-crypt zones to the crypt base associated 
zone (Figure 7F; P < 0.05 for each compartment, compared with 
untreated WT; n = 6–8 mice/group). The fractional representa-
tion of PSCs in the crypt base nearly doubled with DSS treat-
ment in WT mice. The percentage of PSCs in both the upper 
and middle zones showed statistically significant decreases 
(P < 0.05; Figure 7F).
The Myd88-dependent change in the distribution of PSC-positive cells dur-
ing injury requires leukocytes. Adoptive transfer of peripheral blood 
leukocytes from Rag1–/– mice into Myd88–/– mice during the course 
of DSS treatment rescued the epithelial defect in rectal crypts 
(18.5 ± 4.9 M-phase cells/100 crypts and 34.8 ± 2.0 cells/crypt; 
n = 6 mice; compare with Figure 1). The number of PSCs in the 
adoptively transferred Myd88–/– DSS-treated mice was similar to 
those in all other groups (Figure 7E), and the distribution of PSCs 
was similar to that in WT DSS-treated mice (Figure 7F). We con-
Figure 6
PSCs are CD44+ stromal cells. (A–I) Double-labeled, 
immunofluorescence-stained rectal sections from a WT DSS-
treated mouse. (A–C) Sections stained with Zenon Alexa Fluor 
594–labeled anti-Ptgs2 Ig (Invitrogen) (PSCs, red), FITC-labeled 
anti-CD44 Ig (green), and bis-benzimide (blue). All PSCs show 
membrane staining for CD44. Arrowheads denote CD44+ epi-
thelial cells in the crypt base. (A) Ptgs2, (B) CD44, and (C) 
merged image of A and B. (D–F) Two crypt bases from a sec-
tion stained with Zenon Alexa Fluor 594–labeled anti-Ptgs2 Ig 
(PSCs, red) and FITC-labeled anti-CD45 Ig (leukocytes, green). 
(D) Ptgs2, (E) CD45, and (F) merged images (upper panel 
shows a CD45– PSC, and lower panel shows a weakly CD45+ 
PSC). The arrowhead denotes the position of a CD45+ intraepi-
thelial lymphocyte. (G–I) Section stained with (G) Zenon Alexa 
Fluor 594–labeled anti-Ptgs2 Ig (PSCs) and (H) FITC-labeled 
anti-F4/80 Ig (macrophages, green). (I) Merged image of G and 
H. The PSCs in the rectal mesenchyme did not colocalize with 
this or any other marker of differentiated hematopoietic cell lin-
eages. In all panels, the arrows indicate the position of PSCs, 
and the yellow dashed lines indicate the crypt epithelial base. 
Scale bars: 20 μm.
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clude that an influx of Myd88-competent leukocytes (likely either 
monocytes or NK cells, as these are the predominant cell types in 
Rag1–/– blood) enter the gut during DSS-mediated injury and sig-
nal either directly or indirectly to the PSCs.
The crypt base–associated PSCs demonstrated a second aspect of 
their changed location in WT DSS-treated mice, as they appeared 
to be closely associated with the epithelium. We measured the 
shortest distance	of PSCs to the basal surface of the crypt base 
epithelium (stained with integrin α6; Figure 8, A–E). This analy-
sis was performed on the crypt base–associated PSCs. We found 
that this distance was statistically significantly smaller for WT 
DSS-treated mice as well 
as adoptively transferred 
Myd88–/– DSS-treated 
mice as compared with 
all other experimental 
groups (Figure 8E; 2- to 
3-fold decrease; P < 0.001; 
n = 6–8 mice/group, n = 
20–30 cells/mouse). As a 
control, we performed a 
similar evaluation of myo-
fibroblasts (Figure 8, F–J; 
n = 6–8 mice/group, n = 50 
cells/mouse) and PECAM-
posit ive  endothel ia l 
cells (average distances/ 
group = 3.5–4.6 mm from 
the base of crypt epithe-
lial cells; data not shown) 
located in the crypt base 
niche on adjacent sec-
tions of the same mice 
and found no significant 
DSS injury– or Myd88-
dependent alterations in 
the position of these cells 
relative to the base of the 
crypt base epithelium.
Given the recently 
described role for PGE2 
in reinforcing Wnt sig-
naling (28) and our 
results indicating that 
the location of the PSCs 
is critical to maintain 
proliferation during 
DSS-mediated injury, 
we hypothesized that 
relative transcript abun-
dance in the crypt base 
(where ColEPs reside) 
for known Wnt targets 
would be altered dur-
ing DSS injury. Possible 
results were that Wnt 
signaling would be (a) 
increased in WT DSS-
treated ColEPs (relative 
to WT untreated), (b) 
diminished in Myd88–/– DSS-treated ColEPs (relative to Myd88–/– 
untreated), or (c) both a and b together. We found that the first 
scenario occurred. qRT-PCR analysis for matrix metallopeptidase 7 
(Mmp7), CD44, cyclin D1 (Ccnd1), and fos-like antigen 1 (Fosl1) 
using RNAs isolated from LCM-procured crypts bases showed 
no statistically significant differences in Myd88–/– ColEPs (DSS-
treated versus untreated). However, each of these transcripts was 
enriched at least 2.2-fold in WT ColEPs during DSS-mediated 
injury (Table 2). This result indicates that an increase in Wnt 
signaling is required to maintain epithelial proliferation during 
DSS-mediated injury.
Figure 7
Myd88-dependent alteration of PSC distribution toward the crypt base niche in response to DSS-mediated injury. 
(A–D) Double-labeled 60-μm rectal sections immunofluorescently stained with Zenon Alexa Fluor 488–labeled 
anti-Ptgs2 Ig (PSCs, green), Cy3-labeled anti–α-SMA Ig (myofibroblasts, red), and bis-benzimide from (A) WT, 
(B) WT DSS-treated, (C) Myd88–/–, and (D) Myd88–/– DSS-treated mice. Arrows indicate crypt openings. (E) Quan-
tification of PSCs per crypt-surface unit. No significant differences in the numbers of PSCs were observed when 
WT and Myd88–/– DSS-treated mice were compared with their untreated counterparts. AT DSS, Myd88–/– mice 
treated with DSS and an adoptive transfer of peripheral blood leukocytes from Rag1–/– mice. (F) Left: Map for PSC 
quantification in the 3 mesenchymal zones (upper, barrier associated; middle, postmitotic crypt-associated zone; 
lower, proliferative crypt-associated zone). Right: Quantification of PSC fractional representation (FR) for each 
zone. An asterisk indicates a significant difference between DSS-treated mice and untreated controls (*P < 0.05; 
Student’s t test). Both WT DSS-treated and Myd88–/– adoptively transferred DSS-treated mice show a significant 
shift in the fractional representation of PSCs toward the crypt base, while similarly treated Myd88–/– mice did not 
show alteration of PSC position. Scale bars: 30 μm.
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Discussion
Preservation of epithelial proliferation is crucial for proper mainte-
nance of the colonic epithelial barrier. ColEPs from mice that lack 
either Ptgs2 or Myd88 generate an inappropriate hypoproliferative 
state when exposed to DSS (18–21, 26). In this article, we establish 
that Ptgs2 and PGE2 are key downstream targets of Myd88 sig-
naling during DSS-mediated injury that can maintain epithelial 
proliferation in the face of this injury stimulus. An unanticipated 
finding was that the mechanistic link was not through the modula-
tion of either Ptgs2 expression or PGE2 production by Myd88/TLR 
activity, as we initially hypothesized. Instead, Myd88 signaling 
controlled the localization of a population of PSCs, a major source 
of Ptgs2 in the mouse colon (Figure 9). During injury, PSCs altered 
their localization to become more enriched within the crypt base–
associated mesenchyme. In addition, the PSCs in this region were 
more closely associated with the crypt base epithelium, where pro-
liferative ColEPs reside. These 2 PSC redistributions depended on 
Myd88 signaling and were necessary to maintain epithelial prolif-
eration in the response to injury.
Recent studies have begun to dissect the cellular components 
and molecular interactions of cellular niches and their associated 
Table 1
Average picograms of PGE2 per milligram of rectal tissue
Condition	 Sample	1	 Sample	2
WT	 95.9 109.7
WT DSS 77.0 74.6
Myd88–/– DSS 114.7 80.1
Ptgs–/– DSS 111.4 118.5
Figure 8
PSCs were closest to the crypt base epithelium in WT DSS-injured mice. (A–D and F–I) Sections of mouse rectums were stained with FITC-
labeled anti–integrin α6 Ig (green) to label the basal surface of epithelial cells, bis-benzimide, and either (A–D) Zenon Alexa Fluor 594–labeled 
anti-Ptgs2 Ig (PSCs, red) or (F–I) Cy3-labeled anti–α-SMA Ig (myofibroblasts, red). Samples were taken from (A and F) WT untreated, (B and 
G) WT DSS-treated, (C and H) Myd88–/– untreated, and (D and I) Myd88–/– DSS-treated mice. The yellow dotted lines, which indicate minimum 
distance from the PSC or myofibroblasts to the base of the crypt epithelium (all views are of the crypt base only), measure 19 μm (A), 2 μm (B), 
11 μm (C), 16 μm (D), 1.5 μm (F and I), 1.3 μm (G), and 1.7 μm (H). Quantification of distances between the crypt base and (E) PSCs and (J) 
anti–α-SMA–positive myofibroblasts. Mean values ± SEM were plotted for each group. An asterisk indicates a value that is statistically signifi-
cantly different from the corresponding untreated control (*P < 0.001; Student’s t test).
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stem and progenitor cells in a variety of mammalian systems such 
as bone marrow and skin as well as in simpler model organisms 
such the gonads of Drosophila melanogaster and Caenorhabditis elegans 
(for reviews, see refs. 13, 14). All of these systems emphasize the 
close contact of the niche with the target stem cell in order to effect 
proper communication. This study along, with our previous study 
(18), emphasizes that during specific perturbations, the colonic 
niche is not a fixed vessel. One mechanism of injury adjustment is 
the recruitment of additional cellular constituents. We previously 
found that activated macrophages, likely recruited from blood 
monocytes, are one key cell type that performs this function in the 
intestine (18). PSCs appear to be recruited from a much more local 
cellular pool that is not expanded during injury and are a second 
cell type that is mobilized to the crypt niche to become juxtaposed 
to ColEPs during injury.
Several lines of evidence suggest that epithelial proliferation is 
preserved in WT mice treated with DSS by the altered distribu-
tion of PSCs and their generation of PGE2. First, in the absence 
of TLR signaling, neither PSC repositioning nor preservation 
of proliferation during injury occurs. Second, in the absence of 
Ptgs2, there is no preservation of proliferation. Third, in both 
Myd88–/– and Ptgs2–/– mice, epithelial proliferation is maintained 
by the administration of a stable analog of PGE2. The key event in 
preserving epithelial proliferation appears to be the achievement 
of high levels of PGE2 in the pericryptal niche. PGE2 has a short 
half-life and acts over short distances (34, 35). Therefore, PSCs 
positioned closer to crypt epithelial cells should increase the local 
concentration of PGE2. In WT mice, PGE2 levels in the pericryptal 
region are increased by moving the PGE2-producing cells closer; we 
were able to achieve the same effect in Myd88–/– and Ptgs2–/– mice 
by administering a stable analog of PGE2. The mechanism of the 
redistribution of the PSCs is unknown, and we hypothesize that 
this occurs by cell migration in response to either a chemotactic 
factor or basement membrane modification. It is possible that this 
same factor could recruit activated macrophages as well.
Total rectal PGE2 content is similar in all the conditions tested, 
including in DSS-treated Ptgs2–/– mice, suggesting that the major-
ity of the rectal PGE2 is synthesized through Ptgs1. These data 
are consistent with previous studies demonstrating the presence 
of large numbers of Ptgs1-expressing cells and small numbers of 
Ptgs2-expressing cells in the gastrointestinal tract (22–24) and 
that the intestinal PGE2 levels are decreased in Ptgs1–/– mice (26). 
It is important to note that the rectal PGE2 level represents the 
integration of numerous PGE2 microenvironments within this 
tissue. Current methods do not allow measurement of PGE2 lev-
els in specific microenvironments. It is reasonable to assume that 
although Ptgs2 does not contribute extensively to total rectal 
PGE2 levels, it does contribute significantly to PGE2 synthesis in 
the immediate neighborhood of PSCs.
In these studies, epithelial proliferation was maintained during 
DSS-mediated injury by repositioning PSCs without any increase in 
Ptgs2 expression or PGE2 production. Ex vivo, TLR ligands given in 
pharmacologic quantities can induce Ptgs2 expression in cells that 
do not constitutively express Ptgs2, such as macrophages and myo-
fibroblasts (36, 37). Increased Ptgs2 expression is commonly associ-
ated with markedly increased PGE2 production. Here, in response 
to the modest level of injury seen in DSS colitis, TLR signaling 
induces the repositioning of PSCs without (a) inducing higher lev-
els of Ptgs2 expression in those cells, (b) inducing Ptgs2 expression 
in cells that do not normally express Ptgs2, or (c) increasing overall 
PGE2 production in the colon. The importance of the positioning 
of PSCs to locally provide PGE2 to ColEPs during injury is support-
ed by a recently published study that shows PGE2 affects epithelial 
proliferation by enhancing Wnt signaling in colonic tumor cells 
(25). Importantly, loss of Wnt signaling in a normal mouse creates 
a colonic phenotype that is similar to that of DSS-treated Myd88–/– 
mice (12). Thus, PSCs may be mobile elements that can support 
critical growth factor pathways during certain types of damage.
These findings may have applications for injury in other organs 
outside of the gut. Ptgs2 and PGE2 play positive roles in wound 
response and healing in bone marrow	injured by chemotherapeutic 
drugs and in bone injured by fractures (38, 39). Myd88 signaling 
has recently been shown to be required for resistance of lung epi-
thelial cells to bleomycin injury (40). Our studies suggest that the 
linkage of Myd88 and Ptgs2 signaling may occur in these other tis-
sues. If so, then the role of the positioning of PSCs with regard to 
tissue stem cells would be of interest. The advantage of the colonic 
injury system as a model for uncovering and quantifying cellular 
Table 2
Fold difference (as determined by qRT-PCR) of transcripts 
in the crypt base, comparing DSS-treated mice to untreated 
counterparts
Mice	 Transcripts
	 CD44	 Fosl1	 Ccnd1	 Mmp7
WT 7.1 ± 1.1 3.6 ± 0.8 2.4 ± 0.3 2.2 ± 0.9
Myd88–/– 1.3 ± 0.5 1.1 ± 0.8 1.1 ± 0.4 1.2 ± 0.4
Figure 9
Model of the key cells that maintain ColEP proliferation and crypt mor-
phology during DSS-mediated injury. Required cellular elements in this 
system are luminal microbes (green), activated macrophages that con-
tain long cellular processes near the crypt base (pink), and PSCs (yel-
low) that relocate to the crypt base near the activated macrophages 
and adjacent to the ColEPs.
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redistribution is the well-defined microanatomy and organization 
of the epithelium and its associated mesenchyme.
In conclusion, this model supports the concept that the niche 
established by pericryptal cells is important in regulating epithelial 
cell proliferation in the colon. It also supports the suggestion that 
PGE2 promotes epithelial proliferation and epithelial homeostasis 
in the face of injury. One aspect of the model that we believe to 
be novel	is the demonstration that a population of PSCs is reposi-
tioned in response to injury and promotes epithelial homeostasis 
through PGE2 production. Thus, the pericryptal niche is even more 
plastic than previously thought, and the cellular composition of 
the niche is modulated in response to injury. The second aspect of 
this model that we believe to be novel is the demonstration that the 
repositioning of the PSCs is Myd88 dependent. This observation 
provides a mechanism for the more severe DSS-induced colitis seen 
in Myd88–/– mice (18–21). A future goal will be to better define the 
PSC cell type and its properties in the intestine and extraintestinal 
sites. The challenge will be to isolate these mesenchymal cells with-
out inducing Ptgs2 in additional cell populations.
Methods
Mice. All experiments involving animals were approved by the Washing-
ton University School of Medicine Animal Studies Committee. All mice 
were maintained in a specific pathogen–free barrier facility under a strict 
12-hour light/dark cycle and fed the same autoclaved chow diet (B&K 
Universal Ltd.) as was fed to germ-free counterparts that were used in our 
previous experiments (18). Adult (6- to 10-week-old) male mice were used 
for all experiments. Knockout strains (Myd88–/–, ref. 41, and Ptgs2–/–, ref. 
42) were backcrossed more than 10 generations on a B6 background (The 
Jackson Laboratory). WT controls were the parental B6 strain.
A 2.5% aqueous solution of DSS (TdB Consultancy) was passed through 
a 0.22-μm cellulose acetate filter and then administered to mice for 7 days 
as drinking water. Control groups of mice received water alone. dmPGE2 
(Cayman Chemical) was dissolved in ethanol (10 mg/ml) and diluted into 
sterile 5% sodium bicarbonate immediately before use (2 μg/ml). Each 
mouse received i.p. injections of this solution twice per day (10 μg/kg body 
weight) for 7 days, concurrent with DSS treatment.
For adoptive transfer experiments, peripheral blood from B6 male 
donor Rag1–/– mice was collected via the posterior vena cava and placed 
in a heparinized tube. To purify leukocytes, the blood was underlaid with 
Lympholyte (Cedarlane Laboratories Ltd.) in a 3:2 ratio and subjected to 
centrifugation (900 g, 20 minutes, 24°C). The buffy coat was collected and 
washed with sterile PBS, and then centrifuged (325 g, 10 minutes, 24°C). 
The cell pellet was collected and then suspended in a solution containing 
0.1% BSA in sterile PBS. Acceptor mice were anesthetized with a solution 
consisting of 87 mg ketamine/kg body weight and 13 mg xylazine/kg 
body weight. Purified leukocytes were retroorbitally injected (15 × 106 
cells/injection in 100 μl of 0.1% BSA in PBS). Injections were performed 
on 3 consecutive days during DSS treatment (days 4, 5, and 6). Mice were 
then sacrificed on day 7, and their colons were collected, fixed in Bouin 
fixative, and blocked in paraffin for histological analysis.
Histochemical and immunohistochemical analyses. All analysis was performed 
on samples from the rectum (see Figure 1A for specific region). For mor-
phometric analysis and a subset of immunohistochemical studies, colons 
were dissected, placed in Bouin fixative for 4 hours at 24°C, and embedded 
in 2% agar for routine paraffin processing. Serial 5-μm-thick sections were 
cut perpendicular to the crypt-surface epithelial cuff axis and parallel to 
the cephalocaudal axis. Sections were stained with H&E or PAS/AB.
For a subset of immunohistochemical studies, cycling cells were labeled 
in S phase by i.p. injection of a solution containing BrdU (120 mg/kg) and 
5′-fluor-2′-deoxyuridine (12 mg/ml; Sigma-Aldrich) 1 hour prior to sacrifice. 
S-phase cells were identified in tissue sections using goat anti-BrdU Ig (30).
For a subset of immunohistochemical studies, colons were dis-
sected as described above and were fixed for 15 minutes at 24°C in 1% 
paraformaldehyde, 75 mM lysine, 75 mM NaPO4, pH 7.4. The specimens 
were washed 3 times for 5 minutes in PBS, pH 7.4, 5% sucrose at 24°C, and 
were frozen in Optimal Cutting Temperature compound (Tissue-Tek) in 
flat sheets to optimize orientation. For direct immunofluorescence, either 
5- or 60-μm-thick sections were additionally postfixed in methanol (5 min-
utes at –20°C) and were blocked in 1% BSA/0.2% nonfat dry milk in PBS 
for 15 minutes at 24°C. Sections were stained with Alexa Fluor 488–labeled 
Armenian hamster mAbs against CD3ε (T cells; clone 145-2C11; BD Biosci-
ences — Pharmingen; 1:50 dilution), FITC-labeled rat mAbs against B220 
(B cells; clone RA3-6B2; BD Biosciences — Pharmingen; 1:50), Alexa Fluor 
488–labeled rat anti-mouse F4/80 (macrophages; clone CI:A3-1; CALTAG 
Laboratories; 1:50), FITC-labeled rat anti-mouse CD45 (leukocyte common 
antigen, Ly-5; clone 30-F11; BD Biosciences — Pharmingen; 1:100), FITC-
labeled rat anti-mouse CD11c (DCs; clone HL3; 1:50); PE-labeled rat CD70 
(clone FR70; BioLegend; 1:100), Cy3-labeled mouse anti–α-SMA (myofibro-
blasts; clone 1a4; Sigma-Aldrich; 1:2,000), rabbit neuron β-tubulin (ganglion 
cells; CRP Inc.; 1:1,000), Gr-1 (neutrophils and eosinophils; clone RB6-8C5; 
BD Biosciences — Pharmingen; 1:100), rat anti-mouse CD31 (endothelial 
cells; clone MEC13.3, BD Biosciences — Pharmingen; 1:100), rat IgG2a 
anti-human/anti-mouse CD49f (integrin α6; clone NKI-GoH3; Chemicon 
International), rat IgG2b anti-mouse CD44 (clone IM7; BD Biosciences 
— Pharmingen), rabbit anti-pan laminin (Sigma-Aldrich), rat IgG2a anti-
human prolyl 4-hydroxylase (clone ER-TR7; BMA Biomedicals), rabbit anti-
human S100 A4 ab-8 (FSP1; Lab Vision Corp.), and mouse IgG1 anti-Ptgs2 
mAb (clone 33; BD Biosciences; 1:50). The Zenon Antibody Labeling system 
(Invitrogen) was utilized for labeling rabbit antibodies and mouse mAbs 
according to the manufacturer’s instructions. Antibodies against insulin 
were used as a negative control for mouse IgG1 (clone Z006; Zymed).
Sections were viewed with a Zeiss Axiovert 200 with AxioCam MRm cam-
era and with ApoTome optical sectioning slider. Two-dimensional render-
ing of 3-dimensional images (for 60-μm sections) was performed using 
Adobe Photoshop CS2 to compile stacked images at 3-μm intervals.
PGE2 assay. Lipids were extracted by homogenizing flash-frozen tissue in 
70% cold ethanol, 30% monobasic sodium phosphate (0.1 M), pH 4.0, fol-
lowed by shaking incubation for 30 minutes at 24°C. Homogenates were 
centrifuged at 1,000 g for 10 minutes. Triplicate aliquots of supernatant 
were dried under nitrogen, and a PGE2 concentration was determined by 
ELISA (Cayman Chemical).
LCM and qRT-PCR analysis. Colons from untreated and DSS-treated mice 
were prepared for LCM using protocols described in ref. 31. The lamina 
propria mesenchyme and epithelium were separately harvested using a 
PixCell IIe System and CapSure HS LCM caps (Arcturus; n = 3 mice per 
experimental group; 10,000 cells harvested/compartment/mouse). Total 
cellular RNA was extracted (PicoPure RNA Isolation kit; Arcturus) and its 
quality evaluated using an Agilent Technologies 2100 Bioanalyzer. Ran-
dom primed cDNA synthesis was used as a template for qRT-PCR that 
was performed in triplicate for each biologic sample using SYBR Green 
Master Mix (Stratagene; all reagents from Invitrogen). The CT for each 
amplicon was determined as the PCR cycle at which the fluorescence 
intensity crosses a user-established threshold. The following primers 
were used: E-cadherin (5′-GTCAACACCTACAACGCTGCC; 5′-GTTGT-
GCTCAAGCCTTCGC), vimentin (5′-CTTGAACGGAAAGTGGAATCCT 
and 5′-GTCAGGCTTGGAAACGTCC), 18S (5′-CATTCGAACGTCT-
GCCCTATC and 5′- CCTGTGCCTTCCTTGGA), Ptgs2 (5′-TGCCTG-
GTCTGATGATGTATG and 5′-GGGGTGCCAGTGATAGAGTG), PECAM 
(5′-TGCACCCATCACTTACCACC and 5′-CTTCATCCACCGGGGCTATC), 
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CD11c (5′-GCAGGAGTGTCCAAAGCAAGA and 5′-CGTGTGCTAG-
GTCTCTGAAGC), F4/80 (5′-GCTGCCAAGTTAATGGACTCA and 5′-ACT-
GTGGAAAGCACCATGTTAG), Iigp1 (5′-CAGGACATCCGCCTTAACTGT 
and 5′- AGGAAGTAAGTACCCATTAGCCA), Reg3g (5′-CTATGAACCCAA-
CAGAGGTGGA and 5′-CACTTCAGAAATCCTGAGGCTC), Indo (5′-ATT-
GGTGGAAATCGCAGCTTC and 5′-ACAAAGTCACGCATCCTCTTAAA), 
Mmp7 (5′-ACTTCAGACTTACCTCGGATCG and 5′-TCCCCCAACTA-
ACCCTCTTGA), Fosl (5′-GCGGAGACCGACAAATTGGA and 5′-TTCT-
GGGATTTTGCAGATGGG), Ccnd1 (5′-TTGTGCATCTACACTGACAACTC 
and 5′-AGGGTGGGTTGGAAATGAACT), and CD44 (5′-TCCAGTCATAG-
TACAACCCTTCA and 5′-GCTCTTAGTGCTAGATGGCAGA).
Statistics. For calculations to determine statistical significance, a 1-
tailed, homoscedastic Student’s t test was used. SEMs were taken from 
calculations of respective SDs. All such calculations were performed 
using Microsoft Excel 2003.
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